Talimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinoma
Date
2022
Authors
Cilento, M.A.
Klein, O.
Egan, E.
Roberts‐Thomson, R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Australasian Journal of Dermatology, 2022; 63(3):e222-e225
Statement of Responsibility
Michael A. Cilento, Oliver Klein, Elizabeth Egan, Rachel Roberts-Thomson
Conference Name
Abstract
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous tumour of neuroendocrine cell origin, which can grow rapidly and metastasise early. Localised disease is treated with surgery and radiotherapy. Disease that reaches a more advanced stage can be treated with a variety of different treatment modalities including surgery, radiotherapy, chemotherapy, radionuclide therapy, immunotherapy, and intralesional therapy. We report a case of a patient who had exhausted all local and systemic treatment options and who subsequently had an exceptional response to intralesional injection of Talimogene laherparepvec (TVEC).
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2022 The Authors. Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.